Tomoko Tadokoro

1.5k total citations
74 papers, 933 citations indexed

About

Tomoko Tadokoro is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Tomoko Tadokoro has authored 74 papers receiving a total of 933 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hepatology, 28 papers in Epidemiology and 20 papers in Molecular Biology. Recurrent topics in Tomoko Tadokoro's work include Liver Disease Diagnosis and Treatment (22 papers), Hepatocellular Carcinoma Treatment and Prognosis (16 papers) and MicroRNA in disease regulation (14 papers). Tomoko Tadokoro is often cited by papers focused on Liver Disease Diagnosis and Treatment (22 papers), Hepatocellular Carcinoma Treatment and Prognosis (16 papers) and MicroRNA in disease regulation (14 papers). Tomoko Tadokoro collaborates with scholars based in Japan, China and United States. Tomoko Tadokoro's co-authors include Asahiro Morishita, Tsutomu Masaki, Koji Fujita, Kyoko Oura, Joji Tani, Takashi Himoto, Hisakazu Iwama, Hirohito Yoneyama, Takako Nomura and Hideki Kobara and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Tomoko Tadokoro

62 papers receiving 922 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomoko Tadokoro Japan 20 400 286 275 224 191 74 933
Jue Wei China 17 487 1.2× 272 1.0× 302 1.1× 181 0.8× 157 0.8× 30 934
Kyoko Oura Japan 19 513 1.3× 305 1.1× 411 1.5× 306 1.4× 238 1.2× 72 1.2k
Romain Désert United States 14 287 0.7× 209 0.7× 164 0.6× 168 0.8× 82 0.4× 28 694
Hisaaki Miyoshi Japan 16 407 1.0× 191 0.7× 177 0.6× 130 0.6× 101 0.5× 40 803
Cristian Perna Spain 15 246 0.6× 314 1.1× 101 0.4× 227 1.0× 208 1.1× 47 1.0k
Gonzalo Carrasco-Aviño Chile 15 266 0.7× 238 0.8× 152 0.6× 112 0.5× 88 0.5× 40 751
Chengyong Qin China 19 313 0.8× 257 0.9× 187 0.7× 214 1.0× 114 0.6× 46 862
Xiaojia Song China 14 412 1.0× 163 0.6× 193 0.7× 128 0.6× 397 2.1× 19 967
Hajime Sunagozaka Japan 20 296 0.7× 401 1.4× 138 0.5× 457 2.0× 207 1.1× 42 1.1k
Andrea Marengo Italy 9 265 0.7× 544 1.9× 159 0.6× 296 1.3× 55 0.3× 12 892

Countries citing papers authored by Tomoko Tadokoro

Since Specialization
Citations

This map shows the geographic impact of Tomoko Tadokoro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoko Tadokoro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoko Tadokoro more than expected).

Fields of papers citing papers by Tomoko Tadokoro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoko Tadokoro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoko Tadokoro. The network helps show where Tomoko Tadokoro may publish in the future.

Co-authorship network of co-authors of Tomoko Tadokoro

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoko Tadokoro. A scholar is included among the top collaborators of Tomoko Tadokoro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoko Tadokoro. Tomoko Tadokoro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tadokoro, Tomoko, Joji Tani, Kei Takuma, et al.. (2025). Decompensated Cirrhosis with Hepatopulmonary Syndrome in a Patient with Interrupted Treatment for Hypopituitarism. Internal Medicine. 64(15). 2307–2311.
2.
Mimura, Shima, Asahiro Morishita, Kyoko Oura, et al.. (2025). Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging Targets. Journal of Clinical Medicine. 14(23). 8503–8503.
3.
Fujita, Koji, Kei Takuma, Kyoko Oura, et al.. (2025). Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration. Clinical and Translational Science. 18(3). e70182–e70182.
4.
Tadokoro, Tomoko, Kyoko Oura, M. Nakahara, et al.. (2025). Genetic Polymorphisms of ALDH2 and ADH1B in Alcohol-Induced Liver Injury: Molecular Mechanisms of Inflammation and Disease Progression in East Asian Populations. International Journal of Molecular Sciences. 26(17). 8328–8328. 1 indexed citations
5.
Mimura, Shima, Asahiro Morishita, Kyoko Oura, et al.. (2025). Galectins and Liver Diseases. International Journal of Molecular Sciences. 26(2). 790–790. 2 indexed citations
6.
Tadokoro, Tomoko, Miwa Kawanaka, Kazuhiro Takahashi, et al.. (2025). A Noninvasive Method of Diagnosing Metabolic Dysfunction-Associated Steatohepatitis Using Cytokeratin-18 Fragment and FIB-3 Index. Diagnostics. 15(8). 1023–1023.
7.
Tadokoro, Tomoko, Joji Tani, Asahiro Morishita, et al.. (2024). The Treatment of Hepatocellular Carcinoma with Major Vascular Invasion. Cancers. 16(14). 2534–2534. 6 indexed citations
9.
Oura, Kyoko, Asahiro Morishita, Tomoko Tadokoro, et al.. (2024). Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 25(24). 13590–13590. 8 indexed citations
10.
Tadokoro, Tomoko, Asahiro Morishita, Takashi Himoto, & Tsutomu Masaki. (2023). Nutritional Support for Alcoholic Liver Disease. Nutrients. 15(6). 1360–1360. 26 indexed citations
11.
Oura, Kyoko, Asahiro Morishita, Joji Tani, et al.. (2023). Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy. Cancers. 15(6). 1834–1834. 4 indexed citations
12.
Ogawa, Chikara, Kei Takuma, M. Nakahara, et al.. (2023). Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease. Diagnostics. 13(7). 1245–1245. 10 indexed citations
13.
Morishita, Asahiro, Kyoko Oura, Tomoko Tadokoro, et al.. (2023). MicroRNAs and Nonalcoholic Steatohepatitis: A Review. International Journal of Molecular Sciences. 24(19). 14482–14482. 9 indexed citations
14.
Oura, Kyoko, Asahiro Morishita, Kei Takuma, et al.. (2023). Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival. Cancer Medicine. 12(24). 22023–22037. 2 indexed citations
15.
16.
Takuma, Kei, Shintaro Fujihara, Koji Fujita, et al.. (2022). Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines. International Journal of Molecular Sciences. 23(3). 1667–1667. 3 indexed citations
17.
Tadokoro, Tomoko, Asahiro Morishita, & Tsutomu Masaki. (2021). Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA. International Journal of Molecular Sciences. 22(15). 8139–8139. 46 indexed citations
18.
20.
Morishita, Asahiro, Koji Fujita, Hisakazu Iwama, et al.. (2020). Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma. American Journal of Physiology-Gastrointestinal and Liver Physiology. 318(3). G401–G409. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026